Estimated read time: 1-2 minutes
Sept 29 — UniQure said its gene therapy for Huntington's disease fell short โof the goal of slowing disease progression significantly after four years, sending its US-listed shares plummeting 40% on Tuesday.
The Dutch company โearlier this month applied for US approval of the treatment, AMT-130, after the FDA ended an โ eight-month-long standoff over the adequacy โof data.
Its application was based on โ a 36-month analysis of the trial, in which the therapy slowed โprogression of the brain โdisorder by 75%.
Walid Abi-Saab, uniQure's chief medical officer, said it โ is difficult to speculate on whether the โ Food and Drug Administration will reconsider the application with the new data.
Tuesday's data showed that AMT-130 slowed disease progression by 44% in 12 high-dose patients at 48 months, compared with an updated control group. But the result did not reach statistical significance, the company โsaid.
UNIQURE CITES CHANGES TO CONTROL GROUP
UniQure said control-group โpatients who discontinued follow-up appeared to experience faster disease progression than those who remained, meaning the control data may have understated AMT-130's potential benefit.
"We do think that, beyond three years, the data is really suffering from this survivor bias," Abi-Saab said.
The therapy's effect on disease progression was measured on the cUHDRS scale, a composite measure of โcognitive, motor and functional decline.
It showed a 61% slowing at four years on โTFC, a narrower โfunctional โ measure that assesses a patient's ability to perform everyday activities, such as working, household tasks and self-care.
Guggenheim analyst Debjit Chattopadhyay said a steady measure on TFC counterbalances the lower reading on the cUHDRS scale.
Huntington's disease is a โrare inherited brain disorder โthat causes movement difficulties and triggers โbehavioral changes and cognitive โ decline. No approved โdrugs exist that help slow progression.
(Reporting by Christy Santhosh in Bengaluru; Editing by โSahal Muhammed)








